Show simple item record

dc.contributor.authorO'reilly, Aen_US
dc.contributor.authorLarkin, Jen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-16T11:43:12Z
dc.date.issued2017-07en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28604130en_US
dc.identifier.citationExpert Rev Anticancer Ther, 2017, 17 (7), pp. 647 - 655en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1208
dc.identifier.eissn1744-8328en_US
dc.identifier.doi10.1080/14737140.2017.1341315en_US
dc.description.abstractINTRODUCTION: The success of the immune checkpoint inhibitors in melanoma has reinvigorated the field of immunotherapy. Immune checkpoint inhibitors are now the standard of care in multiple cancer types including lung cancer, head and neck cancer, urothelial cancer and renal cell cancer. The field of immunotherapy is currently expanding rapidly and will be a focus of research and development for decades to come. Areas covered: This review covers the early development of immune checkpoint inhibitors and the changes that occurred in the drug development paradigm to facilitate the development of immunotherapy. The review will summarise the areas into which immune checkpoint inhibitors have been adopted and will review the data that supported this. Furthermore, we will discuss future developments in immunotherapy and the current landscape regarding maximising the potential of immunotherapy in clinical practice. Expert commentary: In the author's opinion, the potential of immunotherapy is vast. To date immune checkpoint inhibition has already delivered durable responses in a proportion of patients with cancer types which were previously universally lethal. The future of immunotherapy will rely upon the intelligent application of translational research to clinical practice, such that immunotherapy can be effective for a wider population and maintain its current growth.en_US
dc.format.extent647 - 655en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectMelanomaen_US
dc.subjectcheckpointen_US
dc.subjectimmune related adverse eventsen_US
dc.subjectimmune related response criteriaen_US
dc.subjectimmunotherapyen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectDrug Designen_US
dc.subjectHumansen_US
dc.subjectImmunotherapyen_US
dc.subjectMelanomaen_US
dc.subjectTranslational Medical Researchen_US
dc.subjectTreatment Outcomeen_US
dc.titleCheckpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14737140.2017.1341315en_US
rioxxterms.licenseref.startdate2017-07en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert Rev Anticancer Theren_US
pubs.issue7en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume17en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record